Aug 20, 2020
A lot can happen in two years. You might have matched into
residency, graduated from fellowship, had a kid... Or several phase
II trials in low grade glioma research could have been
Since the original airing of this episode in May 2018, there
have been a few updates in neuro-oncology. We'll cover some of the
major ones this week in the BrainWaves podcast.
Produced by James E. Siegler, Brian Nahed and Jorg Dietrich.
Music courtesy of Ian Sutherland, Lovira, and Lee Roosevere. The
opening theme was composed by Jimothy Dalton. Sound effects by Mike
Koenig and Daniel Simion. Unless otherwise mentioned in the
podcast, no competing financial interests exist in the content of
this episode. BrainWaves' podcasts and online content are intended
for medical education only and should not be used for clinical
decision making. Be sure to follow us on Twitter @brainwavesaudio
for the latest updates to the podcast.
- McGirt MJ, Chaichana KL, Attenello FJ, Weingart JD, Than K,
Burger PC, Olivi A, Brem H and Quinones-Hinojosa A. Extent of
surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas.
Neurosurgery. 2008;63:700-7; author reply 707-8.
- Shaw EG, Wang M, Coons SW, Brachman DG, Buckner JC, Stelzer KJ,
Barger GR, Brown PD, Gilbert MR and Mehta MP. Randomized trial of
radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial
results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology.
- Schiff D. Low-grade Gliomas. Continuum (Minneap Minn).
- Wen PY and Huse JT. 2016 World Health Organization
Classification of Central Nervous System Tumors. Continuum
(Minneap Minn). 2017;23:1531-1547.
- Bell EH, Zhang P, Fisher BJ, Macdonald DR, McElroy JP, Lesser
GJ, Fleming J, Chakraborty AR, Liu Z, Becker AP, Fabian D, Aldape
KD, Ashby LS, Werner-Wasik M, Walker EM, Bahary JP, Kwok Y, Yu HM,
Laack NN, Schultz CJ, Gray HJ, Robins HI, Mehta MP and Chakravarti
A. Association of MGMT Promoter Methylation Status With Survival
Outcomes in Patients With High-Risk Glioma Treated With
Radiotherapy and Temozolomide: An Analysis From the NRG
Oncology/RTOG 0424 Trial. JAMA Oncol.
- van den Bent MJ, Klein M, Smits M, Reijneveld JC, French PJ,
Clement P, de Vos FYF, Wick A, Mulholland PJ, Taphoorn MJB, Lewis
J, Weller M, Chinot OL, Kros JM, de Heer I, Verschuere T, Coens C,
Golfinopoulos V, Gorlia T and Idbaih A. Bevacizumab and
temozolomide in patients with first recurrence of WHO grade II and
III glioma, without 1p/19q co-deletion (TAVAREC): a randomised
controlled phase 2 EORTC trial. Lancet Oncol.
- Fangusaro J, Onar-Thomas A, Young Poussaint T, Wu S, Ligon AH,
Lindeman N, Banerjee A, Packer RJ, Kilburn LB, Goldman S, Pollack
IF, Qaddoumi I, Jakacki RI, Fisher PG, Dhall G, Baxter P, Kreissman
SG, Stewart CF, Jones DTW, Pfister SM, Vezina G, Stern JS,
Panigrahy A, Patay Z, Tamrazi B, Jones JY, Haque SS, Enterline DS,
Cha S, Fisher MJ, Doyle LA, Smith M, Dunkel IJ and Fouladi M.
Selumetinib in paediatric patients with BRAF-aberrant or
neurofibromatosis type 1-associated recurrent, refractory, or
progressive low-grade glioma: a multicentre, phase 2 trial.
Lancet Oncol. 2019;20:1011-1022.
- Bell EH, Zhang P, Shaw EG, Buckner JC, Barger GR, Bullard DE,
Mehta MP, Gilbert MR, Brown PD, Stelzer KJ, McElroy JP, Fleming JL,
Timmers CD, Becker AP, Salavaggione AL, Liu Z, Aldape K, Brachman
DG, Gertler SZ, Murtha AD, Schultz CJ, Johnson D, Laack NN, Hunter
GK, Crocker IR, Won M and Chakravarti A. Comprehensive Genomic
Analysis in NRG Oncology/RTOG 9802: A Phase III Trial of Radiation
Versus Radiation Plus Procarbazine, Lomustine (CCNU), and
Vincristine in High-Risk Low-Grade Glioma. Journal of clinical
oncology : official journal of the American Society of Clinical
- Breen WG, Anderson SK, Carrero XW, Brown PD, Ballman KV,
O'Neill BP, Curran WJ, Abrams RA, Laack NN, Levitt R, Galanis E,
Buckner JC and Shaw EG. Final report from Intergroup NCCTG 86-72-51
(Alliance): a phase III randomized clinical trial of high-dose
versus low-dose radiation for adult low-grade glioma. Neuro
- Ullrich NJ, Prabhu SP, Reddy AT, Fisher MJ, Packer R, Goldman
S, Robison NJ, Gutmann DH, Viskochil DH, Allen JC, Korf B, Cantor
A, Cutter G, Thomas C, Perentesis JP, Mizuno T, Vinks AA, Manley
PE, Chi SN, Kieran MW and Consortium NFCT. A Phase II Study of
Continuous Oral mTOR Inhibitor Everolimus for Recurrent,
Radiographic-Progressive Neurofibromatosis Type 1-Associated
Pediatric Low-Grade Glioma: A Neurofibromatosis Clinical Trials
Consortium Study. Neuro Oncol. 2020.